Clinical impact of omalizumab treatment in children with severe asthma: Report of a local experience.
In: Archivos argentinos de pediatria, Jg. 117 (2019-04-01), Heft 2, S. e115-e120
academicJournal
Zugriff:
Omalizumab, an anti-IgE monoclonal antibody, is indicated for the treatment of severe asthma. A longitudinal (pre-/post-intervention), observational, analytical study was conducted to assess the clinical and functional course of patients with uncontrolled severe asthma, 16 weeks before and after treatment. Asthma was controlled in 17 cases (p = 0.00001). Exacerbations were reduced by 48.5 % (p = 0.009) and severe crises, by 100 % (p = 0.001). Before omalizumab treatment, 16 patients (94 %) had exacerbations, whereas 10 (59 %) had them after treatment (p = 0.005). None of the patients was hospitalized (p = 0.007). The dose of inhaled corticosteroids was reduced by 20 % (0.002); the number of patients using continuous oral corticosteroids (p = 0.01), salbutamol (p = 0.001), and oral corticosteroids (p=0.003) also decreased. Pulmonary function was not affected. Two patients had mild adverse reactions. Omalizumab achieved an adequate asthma control in patients with severe asthma.
(Sociedad Argentina de Investigación Odontológica.)
Titel: |
Clinical impact of omalizumab treatment in children with severe asthma: Report of a local experience.
|
---|---|
Autor/in / Beteiligte Person: | Giubergia, V ; Ramírez Farías, MJ ; Pérez, V ; Crespi, N ; Castaños, C |
Zeitschrift: | Archivos argentinos de pediatria, Jg. 117 (2019-04-01), Heft 2, S. e115-e120 |
Veröffentlichung: | Buenos Aires : Sociedad Argentina de Pediatría ; <i>Original Publication</i>: Buenos Aires, La Prensa Medical Argentina [etc.], 2019 |
Medientyp: | academicJournal |
ISSN: | 1668-3501 (electronic) |
DOI: | 10.5546/aap.2019.eng.e115 |
Schlagwort: |
|
Sonstiges: |
|